Tests conducted by two third-party labs show asbestos was not present in the single bottle that the FDA’s contracted lab tested, nor was it present in retained samples of the finished lot from which the bottle was produced.
Further, JNJ’s (NYSE:JNJ) investigation showed the testing protocol at said lab deviated from standard practice.
Shares are up 0.6% after hours.
Source: Press Release
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.